Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 12/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | USP10 | Q14694 | 3/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12619043 | 0.91 | S1PR1 (0.42) | S1PR1USP10GRIN2B | |
| SCHEMBL12619054 | 0.89 | S1PR1 (0.56) | S1PR1CYP2C9 | |
| SCHEMBL12619057 | 0.83 | S1PR1 (0.47) | S1PR1CYP2C9USP10 | |
| SCHEMBL12619058 | 0.83 | S1PR1 (0.45) | S1PR1 | |
| SCHEMBL12619059 | 0.83 | S1PR1 (0.47) | S1PR1CYP2C9 | |
| SCHEMBL13303753 | 0.81 | S1PR1 (0.38) | S1PR1CYP2C9USP10ALDH1A1LMNA | |
| SCHEMBL1794958 | 0.81 | S1PR1 (0.55) | S1PR1CYP2C9GRIN2BGRIN1 | |
| SCHEMBL3216422 | 0.77 | S1PR1 (0.59) | S1PR1CYP2C9 | |
| SCHEMBL3203770 | 0.73 | S1PR1 (0.58) | S1PR1CYP2C9 | |
| SCHEMBL12619441 | 0.73 | S1PR1 (0.49) | S1PR1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951825-B2 | Hetero compound | ASTELLAS PHARMA INC. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20100168159-A1 | HETERO COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-07-01 | — | — | US | disclosed |
| US-7678820-B2 | Hetero compound | ASTELLAS PHARMA INC. (JP) | 2010-03-16 | — | — | US | disclosed |
| US-20090076070-A1 | HETERO COMPOUND | ASTELLAS PHARMA INC. (JP) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168159-A1 | HETERO COMPOUND | S1PR1, ENPP2, LPAR1 | S1PR1 1/4885CYP2C9 3139/4885USP10 4213/4885 |
| US-20090076070-A1 | HETERO COMPOUND | S1PR1, ENPP2, LPAR1 | S1PR1 1/4885CYP2C9 3139/4885USP10 4213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.